Mathias Oelke

Dr. Oelke is a scientific co-founder of NexImmune and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. He is also an expert in cellular immunology and T cell research. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing interest developing methods for antigen-specific stimulation of T cells for therapeutic use. He has numerous peer-reviewed publications and is a co-inventor on more than 20 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Prior to joining NexImmune in 2014, Dr. Oelke was, from 2003-2014, on the faculty at the Johns Hopkins University. Earlier in his career Dr. Oelke, who is a chemist by training, received his Ph.D. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in immunotherapy.